Regeneron stock pops on BofA double-upgrade as 2026 catalysts stack up
New York, Jan 7, 2026, 20:51 EST — Market closed Regeneron Pharmaceuticals shares climbed 4.6% on Wednesday after Bank of America upgraded the drugmaker to “Buy” from “Underperform” and raised its price objective to $860. Investing.com The call matters because Regeneron’s stock has been stuck in a tug-of-war: investors want proof the company can defend its eye-medicine franchise as rivals and copycat versions crowd the field, while newer products and pipeline shots sit further out. BofA wrote that earlier worries around the standard-dose version of Eylea have been priced in, and it is now leaning on a faster shift to